FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication
Jan 22, 2021
1 min read
Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.